Haifa, Israel: Hospitalized patients administered cannabis via a metered dose inhaler report symptom relief and no severe adverse effects, according to clinical data published in the journal Palliative & Supportive Care.
Israeli investigators assessed the safety, feasibility, and efficacy of metered dose cannabis inhalation in a group of hospitalized patients. The device allowed for patients to self-administer precise quantities of cannabis in a vaporized (non-combustion) form.
All patients reported reduced pain symptoms following cannabis inhalation. Several subjects also reported relief from nausea and spasticity. No severe adverse effects were reported by any of the study’s participants. Three-quarters of the participants reported the inhaler to be "easy to use."
Authors concluded, "[T]he current study results have demonstrated the feasibility of administrating cannabis using the Syqe Inhaler, allowing for the first time, to administer small, safe, accurate, precise, and reliable dosages of cannabinoids" in a hospital setting.
For more information, contact Paul Armentano, NORML Deputy Director. Full text of the study, "Cannabis treatment in hospitalized patients using the SYQE inhaler: Results of a pilot open-label study," appears in Palliative & Supportive Care.